Cryptocurrencies
Dice Therapeutics Aces Psoriasis Study — but Firm Faces Tough Rivalry
Dice Therapeutics shares leaped on positive data for its lead drug candidate. What comes next? Investors for months were anxiously awaiting the first-ever clinical data from Dice Therapeutics (DICE) . The results didn’t disappoint them. Read more…